drugset
Drugs / Ozenoxacin
last change Oct 2018 re-read 9 days ago

Ozenoxacin

also known as GF-001001-00 · Ozenoxacine · Ozenoxacino · T-3912 · Xepi

Other / unclassified

Developed for
impetigo
Investigated by
Ferrer Internacional S.A.

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) XEPI — 2017-12-11 fda.gov ↗

Trials 3

today
US approved 2017
NCT02090764 · Ph 3 NCT01397461 · Ph 3 NCT01005771 · Ph 2
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT01005771 Sep 2009 → Mar 2010 — Ferrer Internacional S.A. Completed No outcome recorded
Phase 32 trials · 2 met primary
Phase 3 NCT02090764 Jun 2014 → May 2015 impetigo Ferrer Internacional S.A. Completed Met primary
Phase 3 NCT01397461 Mar → Dec 2012 impetigo Ferrer Internacional S.A. Completed Met primary

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as ozenoxacin ClinicalTrials.gov intervention name — accepted as the source's own label NCT01397461 ↗
1

NCT02090764 ↗
Known as GF-001001-00 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01005771 ↗
Known as Ozenoxacine ChEMBL registry synonym — accepted as the source's own label CHEMBL3990047 ↗
Known as Ozenoxacino ChEMBL registry synonym — accepted as the source's own label CHEMBL3990047 ↗
Known as T-3912 ChEMBL registry synonym — accepted as the source's own label CHEMBL3990047 ↗
Known as Xepi ChEMBL registry synonym — accepted as the source's own label CHEMBL3990047 ↗
Modality Other / unclassified “novel topical antibacterial agent” PMID 30365584 ↗ Oct 2018
Route Topical “ozenoxacin 1% cream after twice-daily topical treatment for 5 days in patients with impetigo” PMID 30365584 ↗ Oct 2018